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Abstract
Purpose Concomitant treatment with radium-223 and paclitaxel is a potential option for cancer patients with bone metastases;
however, myelosuppression risk during coadministration is unknown. This phase Ib study in cancer patients with bone metas-
tases evaluated the safety of radium-223 and paclitaxel.
Methods Eligible patients had solid tumor malignancies with ≥2 bone metastases and were candidates for paclitaxel. Treatment
included seven paclitaxel cycles (90 mg/m2 per week intravenously per local standard of care; 3 weeks on/1 week off) plus six
radium-223 cycles (55 kBq/kg intravenously; one injection every 4 weeks, starting at paclitaxel cycle 2). The primary end point
was percentage of patients with grade 3/4 neutropenia or thrombocytopenia during coadministration of radium-223 and paclitaxel
(cycles 2, 3) versus paclitaxel alone (cycle 1).
Results Of 22 enrolled patients, 15 were treated (safety population), with 7 completing all six radium-223 cycles. Treated patients
had primary cancers of breast (n = 7), prostate (n = 4), bladder (n = 1), non–small cell lung (n = 1), myxofibrosarcoma (n = 1), and
neuroendocrine (n = 1). No patients discontinued treatment from toxicity of the combination. In the 13 patients who completed
cycle 3, the rates of grade 3 neutropenia in cycles 2 and 3 were 31% and 8%, respectively, versus 23% in cycle 1; there were no
cases of grade 4 neutropenia or grade 3/4 thrombocytopenia. Breast cancer subgroup safety results were similar to the overall
safety population.
Conclusion Radium-223 was tolerated when combined with weekly paclitaxel, with no clinically relevant additive toxicities.
This combination should be explored further in patients with bone metastases.
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Introduction
Patients with cancer who develop bone metastases face addi-
tional challenges that include increased incidence of skeletal-
related events, reduced quality of life, and increased economic
burden of the disease [1–5]. Combination treatments that utilize
complementary mechanisms of action and non-overlapping
toxicity profiles are a rational choice for these patients, and
there is a clinical need to identify safe and effective combina-
tions that treat both systemic and metastatic disease.
Radium-223 dichloride (radium-223) is a targeted alpha
emitter that mimics calcium and selectively binds to areas of
active bone remodeling [6–8]. It emits high-energy, short-
range (<100 μm) alpha particles that lead to double-stranded
DNA breaks in nearby cells. Prostate cancer preclinical
models have shown that radium-223 may act via a dual mech-
anism of action through cytotoxic effects on tumor cells and
stabilization of the bone microenvironment [9]. Similar find-
ings were observed in breast cancer preclinical models, sug-
gesting efficacy regardless of primary tumor origin [10].
In the phase III ALSYMPCA trial, radium-223 significant-
ly prolonged overall survival (OS) and delayed time to first
symptomatic skeletal event (SSE) when compared with pla-
cebo, and was wel l to lera ted wi th low rates of
myelosuppression in metastatic castration-resistant prostate
cancer (CRPC) patients [11]. These results led to radium-
223 approval for the treatment of CRPC patients with symp-
tomatic bone metastases and no known visceral metastatic
disease [12]. In a randomized phase I/IIa study of metastatic
CRPC patients, radium-223 was administered in combination
with the taxane chemotherapy docetaxel [13]. Compared with
patients who received docetaxel alone, patients co-treated
with radium-223 plus docetaxel had less grade 3/4
treatment-emergent adverse events (AEs), longer
progression-free survival (PFS), and longer time to radio-
graphic or clinical progression [13]. Based on the observed
data, a myelosuppression model was designed.
Combining radium-223 with chemotherapy may broaden
treatment options for patients with malignancies treated with
taxane chemotherapy. Instead of testing each drug combina-
tion in a clinical trial setting, developing a model that predicts
myelosuppression may provide useful data to better under-
stand the myelosuppressive potential of novel drug combina-
tions. Myelosuppression modeling data from a drug with a
mechanism of action similar to that of docetaxel could be used
to support the tool’s validation. For this reason, paclitaxel was
chosen for use in this radium-223 combination study.
Paclitaxel is a taxane chemotherapy that is in the same class
as docetaxel [14]. It exhibits antitumor activity by binding
tubulin and stabilizing nonfunctional microtubule bundles to
block normal mitotic spindle development and subsequent
cell division [15]. Neutropenia is commonly associated with
paclitaxel [16]; however, studies have shown that paclitaxel
had less hematologic toxicity when administered weekly ver-
sus every 3 weeks [14].
Concomitant treatment with radium-223 and paclitaxel is a
possible treatment strategy for cancer patients with bone me-
tastases. Radium-223 and paclitaxel have potentially synergis-
tic mechanisms of action; however, both agents impact hema-
tologic parameters, and myelosuppression risk during coad-
ministration is unknown. As it is in the same class as docetaxel
[14], paclitaxel administered in combination with radium-223
is expected to have a similar tolerability profile as in the ran-
domized phase I/IIa radium-223 plus docetaxel study [13].
Paclitaxel has a generally moderate effect on neutrophil
counts [14], allowing better assessment of the potentially ad-
ditive effect of radium-223 when both are used in combina-
tion. It is clinically relevant to assess overall safety and poten-
tial hematologic toxicity during coadministration of radium-
223 and paclitaxel, as this may be a potentially new combina-
tion treatment strategy for patients with bone metastases. This
open-label, multicenter, nonrandomized phase Ib study eval-
uated the safety and tolerability of concomitant treatment with
radium-223 and paclitaxel in cancer patients with bone metas-
tases. To the best of our knowledge, this study is the first to
evaluate concomitant use of radium-223 and paclitaxel.
Patients and methods
Patient population
Eligible patients were male or female aged ≥18 years, had a
confirmed malignant solid tumor with at least two bone metas-
tases, and were eligible for treatment with paclitaxel as a single
agent. Visceral metastases were allowed. Documentation of
premenopausal or postmenopausal status was required for fe-
male patients; postmenopausal status was defined either by
≥1 year of amenorrhea in the absence of other biologic or phys-
iologic causes or by surgical menopause with bilateral oopho-
rectomy. Premenopausal patients were required to have a serum
pregnancy test within 7 days before starting study treatment.
Male and female patients of reproductive potential were re-
quired to agree to using two acceptable methods of contracep-
tion simultaneously from the time of signing the informed con-
sent form to 6 months after the last radium-223 injection.
Additional inclusion criteria included life expectancy of
≥16weeks, Eastern Cooperative OncologyGroup (ECOG) per-
formance status of 0 or 1, and adequate bone marrow, liver,
kidney, and blood clotting function.
Patients were excluded if they had prior systemic therapy
with radionuclides; imminent or established spinal cord com-
pression; active brain metastases or meningeal tumors; prior
hemibody external radiotherapy; major surgical procedure,
open biopsy, or significant traumatic injury within 28 days
before starting study treatment; bone fracture in weight-
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bearing bones without acceptable orthopedic stabilization
within 4 weeks prior to starting study treatment; confirmed
Paget’s disease of the bone; uncontrolled seizure disorder re-
quiring anticonvulsant medication; severe cardiac conduction
disorders requiring antiarrhythmic therapy (except for beta-
blockers); pleural effusion or ascites causing respiratory com-
promise; ongoing interstitial lung disease; or evidence of pe-
ripheral neuropathy that was greater than grade 1.
Additional exclusion criteria included arterial or venous
thrombotic or embolic events within 6 months before starting
study treatment; deep vein thrombosis within 3 months before
starting study treatment (except for adequately treated
catheter-related venous thrombosis occurring ≥1month before
start of study medication); evidence or history of bleeding
diathesis; unresolved toxicity higher than grade 1 attributed
to any prior therapy or procedure (excluding alopecia or ane-
mia with hemoglobin ≥9 mg/dL); blood transfusion or use of
erythropoietin within 6 weeks prior to start of study treatment;
platelet transfusions within 3 weeks prior to start of study
treatment; use of biologic response modifiers (e.g.,
granulocyte-macrophage colony-stimulating factor [GM-
CSF] or granulocyte colony-stimulating factor [G-CSF]) with-
in 6 weeks prior to start of study treatment; intake of clozapine
within 4 weeks before start of study treatment; or history of
organ allograft, cardiac disease, Crohn’s disease or ulcerative
colitis, bone marrow dysplasia, human immunodeficiency vi-
rus, or active or chronic hepatitis B or C virus requiring anti-
viral treatment. All patients provided written informed
consent.
Study design and treatment
This open-label, multicenter, nonrandomized phase Ib study
(NCT02442063) was designed to evaluate the safety and
tolerability of radium-223 administered in combination with
paclitaxel in cancer patients with bone metastases. Treatment
included up to seven paclitaxel cycles (90 mg/m2 IV per week
as per local standard of care; administered in a 3 weeks on/
1 week off regimen, starting in cycle 1) combined with up to
six radium-223 cycles (55 kBq/kg IV; one injection every
4 weeks, starting at paclitaxel cycle 2; Fig. 1). All patients
were premedicated with corticosteroids and antihistamines
(H1 and H2 antagonists) before each paclitaxel infusion, ac-
cording to local standard of care. Radium-223 was adminis-
tered as a slow injection after the patient had received pacli-
taxel. The primary end point was percentage of patients with
grade 3/4 neutropenia or thrombocytopenia during treatment
with radium-223 plus paclitaxel (cycles 2 and 3) versus pac-
litaxel alone (cycle 1).
Paclitaxel dose reductions and dose delays or interrup-
tions were permitted, to account for individual patient tol-
erance. Neutrophil and platelet counts were required to be
≥1.5 × 109/L and ≥ 100 × 109/L, respectively, before each
paclitaxel administration. Paclitaxel doses scheduled for
days 8 and 15 were permitted to be delayed by up to 2 days;
any delay longer than 2 days was considered a missed dose
that was not replaced. Radium-223 dose reductions were
not permitted. Radium-223 doses could be delayed for up
to 4 weeks (maximum 8 weeks between two injections) for
recovery of AEs. If administration was delayed for
>4 weeks, radium-223 was discontinued and the patient
entered follow-up.
The main study observation period was the first 12 weeks
(i.e., cycles 1–3), which included one cycle of paclitaxel ad-
ministered alone followed by two cycles of radium-223 in
combination with paclitaxel. A 30-day follow-up was planned
for each patient after completion of the last cycle of study
treatment (i.e., final radium-223 injection in cycle 7). The
PATIENTS TREATMENT FOLLOW-UP
Follow-upbScreening
wk 12wk 0 wk 4 wk 8
Paclitaxel therapy
Radium-223 therapy
Main study period
Cycles 1-3
Extended study period
(up to 4 additional cycles)
Cycles 4-7
Cycle 1 Cycle 2 Cycle 3 Cycles 4-7
Inj 1 Inj 2 Inj 3-6
• Male or female
• ≥18 years of age
• Confirmed malignant solid tumor 
with ≥2 bone metastases
• Candidates for paclitaxel treatment 
as single agent
• ECOG PS of 0 or 1
• Adequate bone marrow, liver, and 
kidney function 
7 paclitaxel cycles (90 mg/m2 IV 
per weeka); administered in a 
3-weeks-on/1-week-off regimen
6 radium-223 cycles (55 kBq/kg IV);
1 injection every 4 weeks starting
at paclitaxel cycle 2
Safety follow-up: documentation
of all AEs and SAEs
Fig. 1 Study design. In this phase Ib study, eligible patients were to
receive one cycle of paclitaxel alone, followed by up to six cycles of
radium-223 in combination with paclitaxel. aPer local standard of care.
bSafety follow-up started 30 days after last study drug administration.AEs
adverse events, ECOG PS Eastern Cooperative Oncology Group
performance status, Inj injection, SAEs serious adverse events
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planned duration of treatment was approximately 32 weeks
(i.e., one cycle of paclitaxel alone plus six cycles of paclitaxel
in combination with radium-223 at 4-week intervals plus
30 days follow-up).
The review boards at all participating centers reviewed and
approved the study protocol. The study was conducted in
accordance with the Declaration of Helsinki and the
International Conference on Harmonisation guidelines for
Good Clinical Practice.
Assessments
Safety was monitored and evaluated throughout the study and
30-day follow-up period. Safety assessments included AEs
and laboratory parameters (e.g., blood tests). AEs were ana-
lyzed using the National Cancer Institute’s Common
Terminology Criteria for AEs, version 4.03 (NCI CTCAE
v4.03); separate AE tables were also generated using termi-
nology from the Medical Dictionary for Regulatory Activities
(MedDRA) version 19.1. Blood samples to determine platelet
and neutrophil counts for the primary end point were collected
twice weekly (i.e., every 3–4 days) during cycles 1–3.
Thereafter, blood samples were taken every 2 weeks until
4 weeks after the last radium-223 injection. Analysis of hema-
tologic parameters was performed at local laboratories.
Statistical analysis
Given the exploratory nature of this study, no formal sam-
ple size calculation was performed. All patients who re-
ceived at least one dose of study drug were included in
the safety population. A descriptive subgroup analysis of
patients with breast cancer was performed and compared
with the safety population.
All parameters were summarized using descriptive statis-
tics. Parameters were summarized by treatment and cycle, if
applicable, using SAS version 9.2 or higher. All planned anal-
yses were explorative, and a confirmatory statistical analysis
was not intended.
Results
Patients
The study was conducted at five centers in Finland, Israel, and
the United Kingdom from August 18, 2015 to October 24,
2016. Of the 22 patients enrolled, 15 received at least one dose
of paclitaxel and were included in the safety population
(Supplementary Table S1). Patient demographics and baseline
clinical characteristics are shown in Table 1. Breast cancer was
the most common tumor type, present in 7 (47%) of 15 pa-
tients (breast cancer subgroup). Compared with the safety
population, there were fewer patients in the breast cancer sub-
group with prior taxane therapy (29% vs. 53%), but rates of ≥3
prior chemotherapy regimens were similar (43% vs. 47%).
All 15 (100%) patients received at least one paclitaxel in-
jection. The median number of paclitaxel cycles received was
6 (range, 1–7 cycles), with a median treatment time of
22 weeks (range, 2–30 weeks). A total of 14 (93%) of 15
patients received treatment with radium-223; 1 patient was
withdrawn from the study during cycle 1 and did not receive
a radium-223 dose. The median number of radium-223 injec-
tions received was 5.5 (range, 1–6 injections). A total of 7
(47%) of 15 patients completed treatment with six radium-
223 injections and seven paclitaxel infusions.
Eight (53%) of 15 patients discontinued study treatment.
The primary reasons for treatment discontinuation were radio-
logic disease progression (27%), AEs associated with disease
progression (7%), AEs not associated with disease progres-
sion (13%), and patient withdrawal (7%). No patients
discontinued treatment because of toxicity from the treatment
combination.
Breast cancer patients, versus the safety population, had a
slightly longer median treatment duration for radium-223 (6
vs. 5.5 cycles) and paclitaxel (7 vs. 6 cycles), and more pa-
tients who completed six radium-223 doses (57% vs. 47%).
Treatment discontinuation related to disease progression oc-
curred in 29% of breast cancer patients versus 33% in the
safety population.
Primary end point
In the safety population, 13 (87%) of 15 patients complet-
ed treatment cycles 1–3 and were included in the analysis
of the primary end point. In these patients, grade 3 neu-
tropenia rates were 31% in cycle 2 and 8% in cycle 3,
versus 23% in cycle 1; there were no cases of grade 4
neutropenia or grade 3/4 thrombocytopenia during cycles
1–3 (Table 2). In the breast cancer subgroup, all seven
patients completed treatment cycles 1–3. In these patients,
grade 3 neutropenia rates were 43% in cycle 2 and 14% in
cycle 3, versus 29% in cycle 1; there were no cases of
grade 4 neutropenia or grade 3/4 thrombocytopenia during
cycles 1–3 (Table 2). The overall number of patients with
grade 3/4 neutropenia or thrombocytopenia during the
study (cycles 1–7) is shown by treatment cycle in
Supplementary Table S2. Neutrophil and platelet values
from screening to end of treatment for the safety popula-
tion are shown in Fig. 2. Mean neutrophil levels did not
exceed grade 2 during treatment and tended to recover at
the end of each cycle; however, postbaseline mean neu-
trophil counts did not return to pre-dose levels for the
majority of timepoints (Fig. 2 A). Overall, there did not
appear to be a trend toward declining neutrophil levels
over time, even after six cycles of combination treatment.
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The peaks in mean neutrophil counts observed at cycle 2,
day 8 and cycle 6, day 8 were due to G-CSF, which was
permitted during the study when clinically indicated or at
the discretion of the Investigator. Only one patient took
G-CSF for myelosuppression. Postbaseline mean platelet
counts returned to baseline values at several timepoints
(Fig. 2 B).
The lower grade 3 neutropenia rate observed in cycle 3
versus cycle 2 was likely driven by paclitaxel dose modifica-
tions (either dose interruptions or dose reductions) or G-CSF
use. Overall, 13 (87%) of 15 patients had paclitaxel dose
modifications (interruptions or delays in 11 [73%] and reduc-
tions in 5 [33%]); 5 (33%) patients had radium-223 dose mod-
ifications (all interruptions or delays).
Safety
All 15 (100%) patients in the safety population experienced at
least one treatment-emergent AE (TEAE), and also reported at
least one paclitaxel-related TEAE as determined by the inves-
tigator (Table 3). A total of 10 (67%) of 15 patients
Table 1 Patient demographics
and baseline clinical
characteristics
Characteristics Safety population n = 15 Breast cancer
subgroup n = 7
Age, median (range), years 61 (45–76) 58 (45–68)
ECOG PS, n (%)
0 6 (40) 5 (71)
1 8 (53) 2 (29)
Progressive disease at study entry, n (%) 15 (100) 7 (100)
Status of primary tumor, n (%)
R0, complete tumor resection with all margins
histologically negative
8 (53) 5 (71)
Resected, status of residual tumor unknown 4 (27) 0
Unresected 3 (20) 2 (29)
Breast cancer tumors, n (%) 7 (47) 7 (100)
HER2- 7 (100) 7 (100)
Hormone receptor status
ER+/PR+ 4 (57) 4 (57)
ER+/PR- 1 (14) 1 (14)
ER+/PR unknown 1 (14) 1 (14)
ER-/PR- 1 (14) 1 (14)
Other tumor types, n (%)
Prostate cancer 4 (27) 0
Bladder cancer 1 (7) 0
Non–small cell lung cancer 1 (7) 0
Neuroendocrine cancer 1 (7) 0
Myxofibrosarcoma 1 (7) 0
Number of bone metastases at baseline, n (%)
2 1 (7) 1 (14)
3 3 (20) 1 (14)
4 4 (27) 3 (43)
5 2 (13) 1 (14)
9 3 (20) 0
10 2 (13) 1 (14)
Number of prior chemotherapy regimens, n (%)
0 3 (20) 2 (29)
1 1 (7) 0
2 4 (27) 2 (29)
≥ 3 7 (47) 3 (43)
BC Breast cancer, ECOG PS Eastern Cooperative Oncology Group performance status, ER Estrogen receptor,
HER2 Human epidermal growth factor receptor 2, PR Progesterone receptor, + Positive, − Negative
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Table 2 Grade 3 or 4 neutropenia
or thrombocytopenia in patients
who completed treatment cycles
1–3 (primary endpoint)
Population, cycle Patients, n Neutropenia, n (%) Thrombocytopenia, n (%)
Grade 3 Grade 4 Grade 3 Grade 4
Safety population
Cycle 1 13 3 (23) 0 0 0
Cycle 2 13 4 (31) 0 0 0
Cycle 3 13 1 (8) 0 0 0
Breast cancer subgroup
Cycle 1 7 2 (29) 0 0 0
Cycle 2 7 3 (43) 0 0 0
Cycle 3 7 1 (14) 0 0 0
Scr 1 4 8 11 15 18 22 25 1 4 8 11 15 18 22 25 1 4 8 11 15 18 22 25 1 8 15 1 8 15 1 8 15 1 8 15 EOT
-4
-2
0
2
4
6
8
10
12
14
16
a
b
N
e
u
tr
o
p
h
il
s
 (
G
IG
A
/L
) 
in
 b
lo
o
d
7 elcyC6 elcyC5 elcyC4 elcyC3 elcyC2 elcyC1 elcyC
Day:
Scr 1 4 8 11 15 18 22 25 1 4 8 11 15 18 22 25 1 4 8 11 15 18 22 25 1 8 15 1 8 15 1 8 15 1 8 15 EOT
100
150
200
250
300
350
400
P
la
te
le
ts
 (
G
IG
A
/L
) 
in
 b
lo
o
d
7 elcyC6 elcyC5 elcyC4 elcyC3 elcyC2 elcyC1 elcyC
Day:
Fig. 2 Hematology values over time (means and standard deviations) for neutrophils (a) and platelets (b) in the safety population, from screening to end
of treatment. EOT End of treatment, Scr Screening
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experienced a radium-223–related TEAE as determined by
the investigator.
TEAEs occurring in >15% of patients are shown in Table 4.
Neutropenia was the most common grade 3/4 TEAE; it oc-
curred in 6 (40%) of 15 patients in the safety population and 3
(43%) of 7 patients in the breast cancer subgroup. Three pa-
tients experienced a fracture: one patient had a pathologic
fracture (proximal right humerus) that was considered not se-
rious, one patient had a pathologic L3 fracture that was con-
sidered not serious, and one patient had a non-pathologic right
hip fracture of an unspecified section of the neck of the femur
(femoral neck hip fracture) due to a fall that was considered a
serious AE (SAE) and led to hospitalization; this patient then
experienced sepsis and died. This patient received only one
radium-223 injection, and the fracture occurred 42 days after
the last (only) radium-223 dose. None of the observed frac-
tures were considered related to study drug by the investigator.
Treatment-emergent paclitaxel-related or radium-223–re-
lated adverse events with a severity of grade ≥ 3 are shown
in Supplementary Table S3; hematologic AEs were most com-
monly determined by the investigator as related to paclitaxel
or radium-223 treatment.
A total of six patients experienced 11 SAEs: general phys-
ical health deterioration (grade 5 in 3 patients), fall (grade 3),
hypophosphatemia (grade 3), tachycardia (grade 2), inguinal
hernia (grade 3), pneumonia (grade 2 in 1 patient; grade 3 in 1
patient), femoral neck hip fracture (grade 5; details provided
above), and hydronephrosis (grade 3). There were no deaths
during treatment or within 30 days after permanent treatment
discontinuation. The four patients with grade 5 AEs died
>30 days after treatment discontinuation; the three cases of
grade 5 general physical health deterioration were associated
with clinical disease progression. Details on the patient with
grade 5 hip fracture are discussed above; this patient also had
grade 3 pneumonia classified as an SAE which the investiga-
tor considered related to paclitaxel and to radium-223 treat-
ment. The grade 2 pneumonia SAE was considered related to
paclitaxel, but not to radium-223 according to the investigator.
All other SAEs were considered by the investigators as not
related to either paclitaxel or radium-223 treatment. During
the study, there were no episodes of bleeding or hemorrhage
(any CTCAE grade) and no development of any new primary
malignancy.
Discussion
This open-label, multicenter, nonrandomized phase Ib study
evaluated the safety of concomitant treatment with radium-
223, a targeted alpha therapy, and paclitaxel, a taxane chemo-
therapy, in cancer patients with bone metastases. The primary
end point was percentage of patients with grade 3/4 neutrope-
nia or thrombocytopenia during treatment with radium-223
plus paclitaxel (cycles 2 and 3) versus paclitaxel alone (cycle
1). Paclitaxel was given alone during the first cycle to estab-
lish a baseline comparator for hematologic values observed in
cycles 2 onward when radium-223 was given in combination
with paclitaxel. Due to the high variability of hematologic
changes among patients, a study design with an intra-
individual comparison allowed for the observation of the
Table 3 Treatment-emergent
adverse events Patients with TEAEs, n (%) Safety population,
n = 15
Breast cancer
subgroup, n = 7
Any TEAE 15 (100) 7 (100)
Grade 3 or 4 9 (60) 2 (29)
Grade 5a 2 (13) 2 (29)
Serious 6 (40) 2 (29)
Leading to permanent discontinuation
of study drug
2 (13) 1 (14)
Any paclitaxel-related TEAEb 15 (100) 7 (100)
Grade 3 or 4 8 (53) 3 (43)
Serious 2 (13) 0
Leading to permanent discontinuation
of study drug
1 (7) 0
Any radium-223–related TEAEb 10 (67) 5 (71)
Grade 3 or 4 4 (27) 1 (14)
Serious 1 (7) 0
Leading to permanent discontinuation
of study drug
0 0
aBoth associated with disease progression and unrelated to study treatment
bAs determined by the investigator
TEAEs Treatment-emergent adverse events
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hematologic effect of paclitaxel alone versus radium-223 in
combination with paclitaxel.
In the 13 patients from the safety population who complet-
ed cycles 1–3, grade 3 neutropenia rates were 31% in cycle 2
versus 23% in cycle 1, and 8% in cycle 3 versus 23% in cycle
1; there were no cases of grade 4 neutropenia or grade 3/4
thrombocytopenia during cycles 1–3. When compared with
neutropenia rates in cycle 1 (paclitaxel alone), results showed
that combining treatment with radium-223 and paclitaxel (cy-
cle 2) resulted in an increase in grade 3 neutropenia rates;
however, the combination did not seem to increase rates of
high-grade thrombocytopenia. The lower grade 3 neutropenia
rate observed in cycle 3 versus cycle 2 was likely driven by
paclitaxel dose modifications (either dose interruptions or
dose reductions) or G-CSF use; however, no patients
discontinued treatment due to toxicity from the treatment
combination.
Safety results from the breast cancer subgroup were gener-
ally consistent with those of the safety population.When com-
pared with the safety population, the breast cancer subgroup
had slightly higher hematologic AE rates, but fewer grade 3/4
and serious TEAEs; more breast cancer patients also complet-
ed study treatment. The use of radium-223 in patients with
breast cancer is currently being evaluated in phase II trials
(i.e., NCT02258464, NCT02258451, and NCT02366130).
This study was the first to evaluate concomitant use of
radium-223 and paclitaxel, and it was also the first to enroll
patients with solid tumors not previously studied with radium-
223 (i.e., bladder, non–small cell lung, myxofibrosarcoma,
and neuroendocrine). Study limitations included the small
sample size and the lack of formal or consistent collection of
efficacy data. The small sample size may not have permitted
the identification of AEs or SAEs that could occur with the
combination. Additional study limitations were that patients
with compromised bone marrow function were excluded, as
were patients with an ECOG performance status >1.
Additionally, while it is interesting to compare the breast can-
cer subgroup with the safety population, these results should
be viewed as exploratory and hypothesis-generating given the
small patient numbers. Larger, prospective trials are required
to further evaluate the combination of radium-223 and pacli-
taxel in cancer patients with bone metastases.
Cancer treatment strategies are increasingly using combi-
nation therapies to treat the disease. Successful combinations
often stem from agents with complementary mechanisms of
action and non-overlapping toxicity profiles. In view of the
Table 4 Treatment-emergent
adverse events in >15% of
patients during cycles 1–7
Patients with TEAEs, n (%)a Safety population, n = 15 Breast cancer subgroupb , n = 7
All grades Grade 3 Grade 4 All Grades Grade 3 Grade 4
Hematologic AEs
Anemia 4 (27) 1 (7) 0 3 (43) 1 (14) 0
Leukopenia 3 (20) 2 (13) 0 3 (43) 2 (29) 0
Neutropenia 9 (60) 4 (27) 2 (13) 5 (71) 2 (29) 1 (14)
Nonhematologic AEs
Vision blurred 3 (20) 0 0 1 (14) 0 0
Abdominal pain 5 (33) 1 (7) 0 4 (57) 1 (14) 0
Constipation 4 (27) 1 (7) 0 3 (43) 1 (14) 0
Diarrhea 8 (53) 0 0 4 (57) 0 0
Nausea 5 (33) 0 0 4 (57) 0 0
Vomiting 6 (40) 0 0 5 (71) 0 0
Fatigue 9 (60) 1 (7) 0 5 (71) 0 0
Peripheral edema 5 (33) 0 0 2 (29) 0 0
Urinary tract infection 3 (20) 0 0 1 (14) 0 0
Pain in extremity 3 (20) 1 (7) 0 1 (14) 0 0
Peripheral neuropathy 9 (60) 0 0 6 (86) 0 0
Alopecia 10 (67) 0 0 6 (86) 0 0
Rash 4 (27) 0 0 1 (14) 0 0
aAccording to Medical Dictionary for Regulatory Activities (MedDRA) preferred term. Breast cancer subgroup
according to CTCAE terminology: leukopenia and neutropenia were recorded as white blood cell count decreased
and neutrophil count decreased, respectively
bTEAEs for the breast cancer subgroup were identified using the list of TEAEs occurring in >15% of patients in
the safety population
AEs Adverse events, CTCAE Common Terminology Criteria for Adverse Events, TEAEs Treatment-emergent
adverse events
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known potential for myelosuppression during administration
of radium-223 and paclitaxel as single agents [11, 16], it was
clinically relevant to assess the potential for additive hemato-
logic toxicity during coadministration of the drugs. Since pa-
tients with bone metastases are prone to increased
myelosuppression with systemic chemotherapy, paclitaxel
was chosen to be administered in combination with radium-
223 in this study because it has a generally moderate effect on
neutrophil counts, particularly in patients who have been
heavily pretreated [14]. Additionally, paclitaxel is in the same
drug class as docetaxel [14], so administering paclitaxel in
combination with radium-223 was expected to have a similar
tolerability profile as the randomized phase I/IIa radium-223
plus docetaxel study while generating data for potential new
combination treatment strategies [13]. The paclitaxel dosing
schedule was selected based on studies showing less hemato-
logic toxicity when paclitaxel was administered in weekly
versus every-3-week dosing [14]. Safety and tolerability find-
ings from this study contribute to knowledge of the safety of
radium-223 combined with taxane chemotherapy [13] and
form the basis for the potential evaluation of radium-223 in
other tumor types.
In conclusion, radium-223 was well tolerated when com-
bined with paclitaxel in cancer patients with bone metastases,
with no clinically relevant additive toxicities. In this study,
combining treatment with radium-223 and paclitaxel resulted
in an increase in neutropenia rates; however, thrombocytope-
nia rates did not appear to be impacted. A separate publication
reporting the modeling data and potential mode of interaction
between radium-223 and paclitaxel (whether additive or syn-
ergistic) is under preparation. The combination of radium-223
and paclitaxel should be explored further in cancer patients
with bone metastases.
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